에 대한 최신 뉴스 Insulet (NASDAQ:PODD) 주식

Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Large Cap

News

Movers

Trading Ideas

AFRM

AZPN

NTNX

PODD

TCOM

VEEV

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 어펌 홀딩스(NASDAQ:AFRM)의 주가는 강력한 4분기 실적과 낙관적인 1분기 가이던스에 따라 36.04% 상승했다. 몇몇 분석가는 주가 전망을 상향 조정했다.

어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)

Equities

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Econ #s

Federal Reserve

Tech

ETFs

AVGO

DXCM

MRNA

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XLRE

지난 8 거래일 연속 상승 이후 월스트리트는 잠시 멈췄다. S&amp;P 500과 나스닥 100 지수는 화요일 소폭 하락 마감하여, 각각 2024년 5월과 2023년 10월 이후의 최고의 상승 행진을 멈췄다.

S&amp;P 500, 나스닥 100은 8일 연속 상승 후 소폭 하락 마감: 화요일에 월가의 하락 요인은?

CRBG

DELL

MNDY

MSTR

ONON

SMCI

지난주 이들 대형주들은 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 마이크로스트레티지(NASDAQ:MSTR)의 주가가 비트코인 가격 상승 이후 30.10% 상승했다. 먼데이닷컴(NASDAQ:MNDY)의 주가는 예상보다 나은 1분기 재무 결과와 예상보다 높은 2분기 FY24 매출 지침에 따라 주가는 25.97% 상승했다. 몇몇 분석가들은 이 회사의 목표 가격을 높였다.

지난주 최고의 성과를 보인 마이크로스트레티지를 포함한 10개의 대형주 (5월 12일-18일)

Insulet Corp

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $236 to $269.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $269

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return of 22.61%. Currently, Insulet has a market capitalization of $16.75 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $2,138.90 today based on a price of $238.91 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727204416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Insulet, presenting an average target of $242.4, a high estimate of $285.00, and a low estimate of $220.00. This upward trend is evident, with the current average reflecting a 5.85% increase from the previous average price target of $229.00.
<img src="https://www.benzinga.com/files/images/story/2024/1726599627_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Insulet among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insulet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Insulet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Insulet's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Breaking Down Insulet's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Insulet's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 23.2%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Insulet's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Insulet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.4, Insulet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Insulet's Future

WIIM

Insulet shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $230 to $285.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham cut the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $81 to $78. Needham analyst Gil Blum maintained a Buy rating. Immunocore shares fell 1.6% to close at $33.00 on Monday. <a href="https://www.benzinga.com/quote/IMCR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $41 to $45. Baird analyst Vikram Kesavabhotla maintained an Outperform rating. Doximity shares rose 0.3% to close at $39.44 on Monday. <a href="https://www.benzinga.com/quote/docs/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) price target from $200 to $300. B of A Securities analyst Andrew Obin upgraded the stock from Neutral to Buy. GE Vernova shares rose 1.9% to close at $229.93 on Monday. <a href="https://www.benzinga.com/quote/gev/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) price target from $14.5 to $12.5. Morgan Stanley analyst Javier Martinez downgraded the stock from Overweight to Equal-Weight. Adecoagro shares fell 0.2% to close at $11.55 on Monday. <a href="https://www.benzinga.com/quote/agro/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein slashed the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $174 to $155. Bernstein analyst Richard Clarke maintained an Outperform rating. Airbnb fell 0.2% to close at $117.55 on Monday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) price target from $230 to $285. Piper Sandler analyst Matt O&#8217;Brien maintained an Overweight rating. Insulet shares rose 0.01% to close at $233.89 on Monday. <a href="https://www.benzinga.com/quote/podd/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) price target from $115 to $87. Stifel analyst Paul Matteis maintained a Buy rating. BioMarin Pharmaceutical shares fell 17.7% to close at $69.86 on Monday. <a href="https://www.benzinga.com/quote/bmrn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen cut the price target for Topgolf Callaway Brands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) from $13 to $10. TD Cowen analyst John Kernan maintained a Hold rating. Topgolf Callaway Brands shares rose 2% to close at $10.40 on Monday. <a href="https://www.benzinga.com/quote/modg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel slashed Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) price target from $135 to $130. Stifel analyst Matthew Sheerin maintained a Buy rating. Jabil shares fell 0.2% to close at $105.72 on Monday. <a href="https://www.benzinga.com/quote/jbl/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities raised Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) price target from $37 to $41. B. Riley Securities analyst Lucas Pipes maintained a Neutral rating. Alcoa shares rose 6.1% to close at $34.50 on Monday. <a href="https://www.benzinga.com/quote/aa/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="481" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png" alt="" class="wp-image-551787" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-768x361.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40896687/how-to-earn-500-a-month-from-fedex-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FedEx Stock Ahead Of Q1 Earnings</a></li>
</ul>

Pre-Market Outlook

Markets

ABNB

AGRO

BMRN

DOCS

IMCR

MODG

GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday

Piper Sandler analyst Matt O'Brien maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $230 to $285.

Piper Sandler Maintains Overweight on Insulet, Raises Price Target to $285

In a new SEC filing on September 12, it was revealed that Hopfield, Board Member at Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), executed a significant exercise of company stock options.
What Happened: Hopfield, Board Member at Insulet, made a strategic move by exercising stock options for 7,628 shares of PODD as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001145197/000112760224023843//Archives/edgar/data/1145197/000112760224023843/0001127602-24-023843-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $1,533,151.
The Friday morning market activity shows Insulet shares up by 0.18%, trading at $230.86. This implies a total value of $1,533,151 for Hopfield's 7,628 shares.
<h3>All You Need to Know About Insulet</h3>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Unraveling the Financial Story of Insulet</h3>
Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 23.2%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 67.74%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Insulet's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.69.
</li>
</ul>
Debt Management: Insulet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.4. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 41.68 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 9.29 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 43.84, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001145197">Check Out The Full List Of Insulet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Jessica Hopfield At Insulet Decides to Exercises Options Worth $1.53M

The Nasdaq 100 closed higher by over 400 points during Wednesday's session. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Upstart Holdings</h3>
<ul>
<li>The Trade: Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) CFO Sanjay Datta <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 1,500 shares</a> at an average price of $34.85. The insider received around $52,275 from selling those shares.</li>
<li>What's Happening: On Aug. 20, JP Morgan analyst Reginald Smith maintained Upstart with an Underweight and raised the price target from $27 to $30.</li>
<li>What Upstart Does: Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform.</li>
</ul>
<h3 class="wp-block-heading">Zillow Group</h3>
<ul>
<li>The Trade: Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) President, Zillow Susan Daimler <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 6,031 shares</a> at an average price of $54.16. The insider received around $326,658 from selling those shares.</li>
<li>What's Happening: On Sept. 6, JMP Securities analyst Nicholas Jones reiterated Zillow with a Market Outperform and maintained a $62 price target.</li>
<li>What Zillow Group Does: Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease.</li>
</ul>
<h3 class="wp-block-heading">Intuit</h3>
<ul>
<li>The Trade: Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) EVP, Chief Technology Officer Alex G. Balazs <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 2,941 shares</a> at an average price of $628.76. The insider received around $1.85 million from selling those shares.</li>
<li>What's Happening: On Aug. 22, Intuit reported better-than-expected fourth-quarter financial results and issued FY25 EPS guidance above estimates. Also, the company approved a new $3 billion repurchase authorization.</li>
<li>What Intuit Does: Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte).</li>
</ul>
<h3 class="wp-block-heading">Insulet</h3>
<ul>
<li>The Trade: Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) Director Timothy J Scannell <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 5,000 shares</a> at an average price of $225.84. The insider received around $1.1 million from selling those shares.</li>
<li>What's Happening: On Aug. 26, Insulet said its Omnipod is now indicated for use by people with type 2 diabetes in the US..</li>
<li>What Insulet Does: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Short Ideas

INTU

UPST

Upstart, Insulet And 2 Other Stocks Executives Are Selling

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.75% on an annualized basis producing an average annual return of 22.2%. Currently, Insulet has a market capitalization of $15.36 billion. 
Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 15 years ago, it would be worth $20,354.17 today based on a price of $219.13 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725984011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today

Insulet Corp.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/podd#NASDAQ">PODD</a>) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product&#39;s market potential. The planned launch of Omnipod 5 with Abbott&#39;s Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% growth of the industry and the 24.9% rise of the S&amp;P 500 composite.
The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $14.22 billion. PODD&#39;s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 67.5%.
<h2>Catalysts for PODD Stock</h2>
Omnipod 5, a New Focus: Insulet&#39;s game-changing Omnipod 5 stands out as the only FDA-cleared, fully disposable pod-based AID system. The product attributes, such as on-body wearable, simplicity, ease of use and broad accessibility, are the key drivers of its rapid adoption and are successfully driving market growth. The second quarter saw nearly 85% of the new starts coming from people previously using MDI, Insulet&#39;s target market, while competitive conversions also remained very strong. The company is driving growth rates above 20% in international revenues, underscoring the strong potential for Omnipod 5&#39;s continued expansion. On a promising note, Omnipod 5 recently received the FDA&#39;s usage clearance by people with type 2 diabetes (aged 18 years and above) in the United States.
Expanding Access and Awareness of Omnipod: One of Insulet&#39;s key strategic imperatives is to increase the availability and visibility of Omnipod products. In the second quarter of 2024, Omnipod 5 integrated with Dexcom&#39;s G6 CGM drove 27% growth in U.S. Omnipod revenues. The company began the full market release of Omnipod 5 with G7, available exclusively through several specialty pharmacies.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/98/76485.jpg?v=914640466" /> 
Image Source: Zacks Investment Research
On the latest earnings call, Insulet hinted at launching Omnipod 5 with Abbott&#39;s Freestyle Libre 2 Plus sensor in the United States by the end of this year. The combination had a limited market release in the United Kingdom and the Netherlands during the first quarter. Further, Omnipod DASH is driving strong new customer starts in the U.S. type 2 diabetes market.
Strong Solvency but Leveraged Balance Sheet: Insulet exited the second quarter of 2024 with cash and cash equivalents of $821 million and current debt of $38 million. This robust financial stability appears highly promising during the prolonged period of macroeconomic issues.&nbsp; Long-term debt of $1.36 billion remained marginally in line with the 2024 first-quarter figure.
<h2>Factors Weighing on Insulet Stock</h2>
Economic Uncertainty Hampers Growth: The continuing worldwide macroeconomic and geopolitical uncertainty may reduce the demand for Insulet&#39;s products, intensify competition, exert pressure on prices, dent supply and lengthen the sales cycle. The company continues to experience challenges stemming from the global supply chain disruption. Its reliance on third-party suppliers in China could face potential risks from political or financial instability and labor unrest, among others.
Tough Competitive Pressure:&nbsp;Insulet operates in a highly competitive environment dominated by firms ranging from large multinational corporations with significant resources to start-ups. It also competes with companies offering products and supplies for MDI therapy, which is the most prevalent method of insulin delivery. Regulatory conditions limit the company&#39;s ability to switch to strategies like price increases and other drivers of cost increases. With competitors potentially developing effective patch pumps or breakthrough diabetes treatments that do not require the delivery of insulin, sales of Omnipod may be negatively affected.
<h2>PODD Estimate Trend</h2>
The Zacks Consensus Estimate for Insulet&#39;s 2024 earnings per share has decreased 1.6% to $3.04 in the past 30 days.
The Zacks Consensus Estimate for the company&#39;s 2024 revenues is pegged at $2.01 billion. This suggests an 18.3% rise from the year-ago reported number.
<h2>Top MedTech Stocks</h2>
Some better-ranked stocks in the broader medical space are TransMedix Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), Veracyte (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>) and Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong Buy), Boston Scientific carries a Zacks Rank #2 (Buy).
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its shares have soared 130.6% compared with the industry&#39;s 11% rise in the past year.
TMDX&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%.
Veracyte has an estimated earnings growth rate of 112.8% compared with the industry&#39;s 12.4%. Shares of the company have soared 13.4% compared with the industry&#39;s 10.9% rise over the past year.
VCYT&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 328.4%.
Boston Scientific has an estimated earnings growth rate of 17.1% compared with the industry&#39;s 14.9%. Shares of the company have rallied 51.3% compared with the industry&#39;s 15.5% rise over the past year.
BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
<a href="https://www.zacks.com/stock/news/2331170/should-you-continue-to-retain-podd-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2331170">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

General

TMDX

VCYT

Should You Continue to Retain PODD Stock in Your Portfolio Now?

Prem Singh, SVP at Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), disclosed an insider sell on September 3, according to a recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001145197/000112760224023311//Archives/edgar/data/1145197/000112760224023311/0001127602-24-023311-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that Singh executed a sale of 1,824 shares of Insulet with a total value of $368,940.
Tracking the Wednesday's morning session, Insulet shares are trading at $217.65, showing a up of 5.3%.
<h3>About Insulet</h3>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Understanding the Numbers: Insulet's Finances</h3>
Revenue Growth: Over the 3 months period, Insulet showcased positive performance, achieving a revenue growth rate of 23.2% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 67.74%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Insulet's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 2.69.
</li>
</ul>
Debt Management: Insulet's debt-to-equity ratio surpasses industry norms, standing at 1.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 37.39 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 8.33, Insulet's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 39.48 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001145197">Check Out The Full List Of Insulet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Selling: Prem Singh Unloads $368K Of Insulet Stock

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) shares escalated 36.04% following strong&nbsp;fourth-quarter&nbsp;earnings and <a href="https://www.benzinga.com//node/40613433" target="_blank" rel="noreferrer noopener">upbeat&nbsp;first-quarter&nbsp;guidance</a>. Several analysts raised <a href="https://www.benzinga.com//node/40630056" target="_blank" rel="noreferrer noopener">the price forecasts on the stock</a>.</li>
<li>Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) stock jumped 18.80% after the company reported fourth-quarter&nbsp;financial results and issued&nbsp;first-quarter&nbsp;and FY25 <a href="https://www.benzinga.com//node/40614905" target="_blank" rel="noreferrer noopener">revenue&nbsp;guidance&nbsp;above estimates</a>. Many analysts <a href="https://www.benzinga.com//node/40626089" target="_blank" rel="noreferrer noopener">boosted the stock&#8217;s price target</a>.</li>
<li>Mongodb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) stock gained 16.32% in the last week on better-than-expected Q2 financial results and issued strong guidance. Several analysts bumped <a href="https://www.benzinga.com/quote/MDB/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecasts on the stock</a>.</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) stock increased 13.54% after it reported second-quarter results and raised its <a href="https://www.benzinga.com//node/40624075" target="_blank" rel="noreferrer noopener">FY25 earnings&nbsp;guidance</a>. Several analysts boosted their <a href="https://www.benzinga.com//node/40651188" target="_blank" rel="noreferrer noopener">forecasts on the stock</a>.</li>
<li>GE Vernova Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) upped 11.62% in the last week after William Blair initiated coverage on the stock <a href="https://www.benzinga.com/quote/GEV/analyst-ratings" target="_blank" rel="noreferrer noopener">with an Outperform rating</a>.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) stock upped 11.42% after the company<a href="https://www.benzinga.com//node/40564652" target="_blank" rel="noreferrer noopener"> reported quarterly results</a>.</li>
<li>The Cooper Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) shares were up 11.30% after the company reported third-quarter results and issued&nbsp;above-estimates<a href="https://www.benzinga.com//node/40611992" target="_blank" rel="noreferrer noopener"> fourth-quarter&nbsp;and FY25&nbsp;guidance</a>.&nbsp;Several analysts<a href="https://www.benzinga.com/quote/COO/analyst-ratings" target="_blank" rel="noreferrer noopener"> upped the price target</a>.</li>
<li>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) shares upped 9.94% after the company recently announced its Omnipod is now indicated for use by people <a href="https://www.benzinga.com//node/40562757" target="_blank" rel="noreferrer noopener">with type 2 diabetes in the US</a>.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares were up 8.44% after the company reported&nbsp;financial results and issued&nbsp;third-quarter&nbsp;and FY25 adjusted <a href="https://www.benzinga.com//node/40611557" target="_blank" rel="noreferrer noopener">EPS&nbsp;guidance&nbsp;above estimates</a>. Several analysts bumped the <a href="https://www.benzinga.com/quote/veev/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the company</a>.</li>
<li>Aspen Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) shares were up 8.12%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40675182/dollar-general-temu-parent-pdd-and-super-micro-computer-are-among-top-10-large-cap-losers-last-wee">Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Affirm

Affirm, Mongodb And Best Buy Are Among Top 10 Large Cap Gainers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?

Insulet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) short percent of float has fallen 8.83% since its last report. The company recently reported that it has 2.71 million shares sold short, which is 5.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insulet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725037221_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insulet has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insulet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insulet's peer group average for short interest as a percentage of float is 4.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(PODD) - Analyzing Insulet's Short Interest

Insulet shares are trading higher after the company recently announced its Omnipod is now indicated for use by people with type 2 diabetes in the US.

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 7.89% on an annualized basis producing an average annual return of 18.7%. Currently, Insulet has a market capitalization of $14.16 billion. 
Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 10 years ago, it would be worth $5,552.50 today based on a price of $202.00 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724857226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Insulet Stock In The Last 10 Years

Insulet Corp.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/podd#NASDAQ">PODD</a>) groundbreaking Omnipod 5 Automated Insulin Delivery (&quot;AID&quot;) system (Omnipod 5) received the FDA&#39;s approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial.
With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes.
<h2>Insulet&#39;s Robust Opportunity in the Type 2 Space</h2>
Diabetes is a chronic and life-threatening disease for which there is no known cure. The more common variant, type 2 diabetes, is characterized by the body&#39;s inability to either properly utilize or produce enough insulin. More than 30 million people are living with type 2 diabetes in the United States, with approximately 6 million people requiring insulin. Of these, roughly 2.5 million are using multiple daily injections (&quot;MDI&quot;) &mdash; a form of insulin therapy that involves injecting fast-acting insulin before meals (bolus) to lower blood glucose levels to a healthy range.
Although medical therapies have advanced in the past 20 years, the percentage of adults with type 2 diabetes achieving recommended HbA1c (a common measure of blood glucose levels) targets&nbsp;has not seen any significant change. Only a quarter of individuals with type 2 diabetes on insulin are achieving an HbA1c of 7% or less and half of this population has an HbA1c greater than 8%.&nbsp;Despite guideline recommendations for insulin treatment in advanced disease, insulin therapy is often delayed or not appropriately intensified.
<h2>The SECURE-T2D Trial Boosts Approval of PODD&#39;s Omnipod 5</h2>
This is the largest study ever completed for the use of AID in type 2 diabetes, featuring highly diverse study participants who are representative of the general population in the United States. Insulet recently presented data showing that Omnipod 5 significantly improves health outcomes while making life easier for people with type 2 diabetes.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2f/75532.jpg?v=2091424716" />
Image Source: Zacks Investment Research
The trial demonstrated that compared with prior insulin therapy methods in adults with type 2 diabetes, using Omnipod 5 resulted in considerable reductions in HbA1c &mdash; 0.8% overall and 2.1% in those with prior HbA1c 9% or higher. Time in hyperglycemia and total daily insulin dose were also reduced. In addition, there was a 20% improvement in time in range, increasing 4.8 hours per day, without increasing time in hypoglycemia. The study also demonstrated a clinically meaningful improvement in diabetes distress.
<h2>Insulet&#39;s Omnipod 5 Simplifies Type 2 Diabetes Management</h2>
The latest announcement from the company represents a significant milestone for the treatment of type 2 diabetes, providing an easy-to-use, patient-centric technology. The tubeless pod therapy, Omnipod 5, has set a new standard in diabetes management, allowing individuals to achieve better health outcomes while giving them greater confidence and freedom in their daily lives. Insulet&#39;s president and CEO expressed excitement about the opportunity to make a lasting impact on the insulin-requiring type 2 diabetes community.
The Omnipod 5 System leads to improved results by eliminating the need for MDI and automatically adjusting insulin delivery every 5 minutes, using its advanced SmartAdjust technology. As the top-rated and most prescribed pump in the United States, Omnipod 5 is waterproof, discreet and wearable. This is the first tubeless AID system that communicates with a continuous glucose monitor, proactively correcting for highs and protecting against lows, day and night. The system is easy to prescribe through the pharmacy and widely covered by many insurance plans, including Medicare Part D.
<h2>Insulet&#39;s Prospects in the Type 2 Diabetes Industry</h2>
Per a Precedence Research report, the global market for type 2 diabetes was valued at $32 billion in 2022 and expected to witness a CAGR of 8.2% by 2032.
The introduction of new, more effective and safer therapeutic compounds is paving the way for the development of new treatments. Additionally, the rising obesity epidemic in many regions of the world is boosting the industry&#39;s profitability. &nbsp;
Recent Developments of Insulet
Insulet unveiled its new state-of-the-art manufacturing facility in Malaysia this month, which strategically positions the company to cater to the huge demand for Omnipod. The 400,000-square-foot facility strengthens the company&#39;s global operational capabilities and supply chain resiliency and currently runs with a local workforce that has been upskilled and trained.
<h2>PODD&#39;s Price Performance</h2>
In the past year, Insulet shares have lost 0.3% against the industry&#39;s rise of 14%.
<h2>Zacks Rank and Key MedTech Stocks</h2>
Insulet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Exact Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exas#NASDAQ">EXAS</a>), Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>), and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>). Each of these carries a Zacks Rank #2 (Buy) at present.
Exact Sciences&#39; shares have fallen 25.3% in the past year. Estimates for the company&#39;s loss per share have improved from $1.09 to 95 cents in 2024 and from 26 cents to 6 cents in 2025 in the past 30 days. EXAS&#39; earnings beat estimates in three of the trailing four quarters and matched in one, delivering an average surprise of 56.2%. In the last reported quarter, it posted an earnings surprise of 75.7%.
Estimates for Boston Scientific&#39;s 2024 earnings per share have moved to $2.40 from $2.36 in the past 30 days. Shares of the company have gained 47.8% in the past year compared with the industry&#39;s growth of 13.7%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%. In the last reported quarter, it delivered an earnings surprise of 6.9%.
Estimates for SiBone&#39;s 2024 loss per share have narrowed to 89 cents from 95 cents in the past 30 days. Shares of the company have lost 20.6% in the past year against the industry&#39;s 12.3% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2327736/insulet-s-omnipod-5-wins-fda-approval-for-type-2-diabetes?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2327736">To read this article on Zacks.com click here.</a>

EXAS

SIBN

Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes

Insulet shares are trading higher after the company announced its Omnipod is now indicated for use by people with type 2 diabetes in the US.

Insulet's Omnipod 5 Becomes First FDA-Cleared Automated Insulin Delivery System For Both Type 1 And Type 2 Diabetes, Offering Advanced SmartAdjust Technology To Improve Health Outcomes And Simplify Diabetes Management

After eight consecutive positive sessions, Wall Street hit a pause. The S&amp;P 500 and Nasdaq 100 indices ended Tuesday&#8217;s session with slight declines, halting their best winning streaks since May 2024 <a href="https://www.benzinga.com/markets/equities/24/08/40450395/s-p-500-nasdaq-100-extend-8-session-winning-streak-as-wall-street-jitters-go-poof-mondays-key-st">and October 2023, respectively.</a>
The day was characterized by a lack of economic data, leading to a significant drop in trading volumes across major U.S. stock exchanges. 
Fed Governor Michelle Bowman delivered hawkish comments in the afternoon, stating that she still sees upside risks to inflation. This did little to improve an already negative session.
Bowman further emphasized that wage gains remain above the pace consistent with the Fed's inflation goal, and stressed the need to remain vigilant on the price-stability side of the Fed&#8217;s mandate while monitoring risks of a material weakening in the labor market.
<h3 class="wp-block-heading">Tuesday&#8217;s Major Drags On S&amp;P 500, Nasdaq 100</h3>
The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed down 0.2%. A similar drop was observed in the tech-heavy Nasdaq 100 index, as tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
Sector performance saw three sectors finishing in positive territory and eight in the red:
<ul>
<li>The Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) rose 0.5% </li>
<li>Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) rose 0.4%</li>
<li>The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) edged up by 0.1%.</li>
</ul>
On the downside, energy stocks led the laggards as WTI oil prices fell below $74 per barrel, marking a two-week low. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) dropped 2.6%.
Among individual stocks, Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was the biggest drag on the S&amp;P 500, falling 2.1% and accounting for a 0.15 percentage point loss in the overall index. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) was another significant negative contributor, falling 3.4% and shaving off 0.04 percentage points from the S&amp;P 500 performance. 
The worst performers in the S&amp;P 500 were Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) and DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), which plunged 6.9% and 6.3%, respectively.
In the Nasdaq 100, Nvidia weighed down the index by 0.18 percentage points, followed by Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), which contributed to a 0.05 percentage point loss. The tech index&#8217;s worst performers were DexCom and China&#8217;s PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), the latter dropping 4.6%.
<h3 class="wp-block-heading">Tuesday&#8217;s Worst Contributors To The S&amp;P 500 Performance</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Weight (%)</td>
<td>1-day return (%)</td>
<td>Contribution</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>6.78</td>
<td>-2.14%</td>
<td>-0.15pp</td>
</tr>
<tr>
<td>Exxon Mobil Corporation</td>
<td>1.13</td>
<td>-3.35</td>
<td>-0.04pp</td>
</tr>
<tr>
<td>Broadcom Inc.</td>
<td>1.55</td>
<td>-1.05</td>
<td>-0.02pp</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Tuesday&#8217;s Worst-Performing S&amp;P 500 Stocks</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Insulet Corporation</td>
<td>-6.88</td>
</tr>
<tr>
<td>DexCom, Inc.</td>
<td>-6.27</td>
</tr>
<tr>
<td>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>)</td>
<td>-5.00</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Tuesday&#8217;s Worst Contributors To The Nasdaq 100 Performance</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Weight (%)</td>
<td>1-day return (%)</td>
<td>Contribution</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>8.26</td>
<td>-2.14</td>
<td>-0.18pp</td>
</tr>
<tr>
<td>Broadcom Inc.</td>
<td>5.18</td>
<td>-1.05</td>
<td>-0.05pp</td>
</tr>
<tr>
<td>PDD Holdings Inc.</td>
<td>0.67</td>
<td>-4.55</td>
<td>-0.03pp</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Tuesday&#8217;s Worst-Performing Nasdaq 100 Stocks</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>DexCom, Inc.</td>
<td>-6.27</td>
</tr>
<tr>
<td>PDD Holdings Inc.</td>
<td>-4.55</td>
</tr>
<tr>
<td>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>-3.35</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40466528/jackson-hole-preview-5-important-questions-ahead-of-jerome-powells-fed-speech">Jackson Hole Preview: 5 Important Questions Ahead Of Jerome Powell&#8217;s Fed Speech</a></li>
</ul>

S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?

5 analysts have shared their evaluations of Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $232.4, a high estimate of $250.00, and a low estimate of $220.00. This current average has increased by 1.6% from the previous average price target of $228.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1723492852_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Insulet by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$235.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Insulet's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Insulet's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Understanding the Numbers: Insulet's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Insulet's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.6%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 38.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 21.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Insulet's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.85% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Insulet

Biggest stock movers today: PODD, HIMS, PARA, and more

Analyst Mike Kratky from Leerink Partners reiterated a Buy rating on Insulet (PODD – Research Report) and keeping the price target at $240.00. Mike...

Insulet Stock Buy Rating: FDA Approval Expands Market Reach for Omnipod 5

Wall Street Breakfast: What Moved Markets

Embecta gets FDA clearance for type 2 diabetes patch pump

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at $245.00. Larry...

Strong Growth and Market Leadership Support Buy Rating for Insulet

Fidelity Growth Strategies Fund Q2 2024 Review

Insulet: Turning More Constructive, Valuations Still Stretched

Insulet (PODD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Wood from Morgan...

Insulet's Growth Trajectory Strengthened by Omnipod 5's Expansion into Type 2 Diabetes Market

Fidelity Select Health Care Portfolio Q2 2024 Review

Piper Sandler Sticks to Its Buy Rating for Insulet (PODD)

ALGN

ALNY

BBWI

BMYMP

DLTR

EMBC

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

GKOS

HIMS

IDXX

INSP

LUMN

NONOF

ONEQ

PARA

PARAA

PLTR

PRCT

REGN

RYAAY

SPOT

TNDM

Press Releases

Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024

CereVasc Announces Appointments of New Directors

Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

Insulet Reports Preliminary Second Quarter 2024 Revenue Results

Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year

Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia

Insulet to Present at Upcoming Investor Conferences

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Comments

Insulet

뉴스

에 대한 최신 뉴스 Insulet (NASDAQ:PODD) 주식

화요일, 9월 03, 2024

화요일, 8월 20, 2024

월요일, 5월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌